4.2 Postpartum Hemorrhage (PPH) & Obstetric Hemorrhage Protocols
Key Takeaways
- ACOG defines Postpartum Hemorrhage (PPH) as a cumulative blood loss >= 1,000 mL or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours of birth regardless of delivery route.
- The 4 Ts framework categorizes PPH etiologies: Tone (uterine atony, 70-80%), Tissue (retained placenta/clots), Trauma (lacerations, hematomas, inversion), and Thrombin (coagulopathies).
- Methylergonovine (Methergine) is strictly contraindicated in patients with hypertension or preeclampsia, while Carboprost tromethamine (Hemabate) is strictly contraindicated in patients with asthma or reactive airway disease.
- For clinically diagnosed postpartum hemorrhage, give tranexamic acid 1 g IV as soon as possible and within 3 hours of birth in addition to standard treatment when no contraindication exists; a second 1-g dose may be used if bleeding continues after 30 minutes or restarts within 24 hours.
- Quantitative blood-loss methods improve recognition compared with visual estimation; apply calibrated collection and gravimetric measurement through the facility hemorrhage protocol.
4.2 Postpartum Hemorrhage (PPH) & Obstetric Hemorrhage Protocols
Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and preventable mortality worldwide. Inpatient obstetric nurses must be skilled in early quantitative blood loss detection, rapid systematic etiology identification, and protocolized multidisciplinary resuscitation.
PPH Definition & Classification
Updated ACOG Definition
Postpartum hemorrhage is defined as cumulative blood loss >= 1,000 mL OR blood loss accompanied by signs or symptoms of hypovolemia (tachycardia, hypotension, oliguria, pallor, altered mental status) within 24 hours of the birth process, regardless of delivery route (vaginal or C-section).
Temporal Classification
- Primary (Early) PPH: Occurs within the first 24 hours post-delivery. Most commonly caused by uterine atony (70% to 80% of cases).
- Secondary (Late) PPH: Occurs from 24 hours up to 12 weeks post-delivery. Most commonly caused by retained placental fragments, uterine subinvolution, or pelvic infection.
Quantitative Blood Loss (QBL) vs. Estimated Blood Loss (EBL)
Visual estimation of blood loss (EBL) is notoriously inaccurate, underestimating actual blood loss by 30% to 50%. Quantitative blood-loss methods are recommended to improve recognition and are implemented through the facility protocol:
- Gravimetric Measurement: Weighing all blood-soaked materials (pads, sponges, under-buttocks drapes). 1 gram of weight increase = 1 mL of blood loss. (Net Weight = Wet Weight in grams minus Dry Weight in grams).
- Volumetric Measurement: Direct measurement of fluid volume in calibrated collection drapes (subtracting irrigation fluids).
Etiology: The 4 Ts Framework
When PPH is identified, the nurse and obstetric team must systematically evaluate the 4 Ts to pinpoint the underlying etiology:
| Etiology Category | Specific Causes & Clinical Presentation | Frequency & Key Risk Factors |
|---|---|---|
| 1. Tone (Uterine Atony) | Soft, boggy, uncontracted uterus; inability of myometrium to constrict spiral arteries. | 70–80% of PPH. Risk factors: Uterine overdistension (macrosomia, twins, polyhydramnios), prolonged or precipitous labor, high parity, chorioamnionitis, magnesium sulfate infusion. |
| 2. Tissue (Retained Fragments) | Retained placenta, succenturiate placenta lobe, placenta accreta spectrum; persistent bleeding with partially contracted fundus. | 10–15% of PPH. Risk factors: Incomplete placental inspection at delivery, prior C-section, uterine curettage history. |
| 3. Trauma (Lacerations & Hematomas) | Cervical/vaginal/perineal lacerations, vulvar/vaginal hematoma, uterine rupture, uterine inversion. | 15–20% of PPH. Presentation: Continuous bright red trickling blood despite a FIRM, contracted fundus; severe unremitting rectal/perineal pressure (hematoma). |
| 4. Thrombin (Coagulopathy) | Preexisting (Von Willebrand disease, ITP) or acquired coagulopathy (DIC secondary to abruption, severe preeclampsia, HELLP, amniotic fluid embolism). | < 1% of PPH. Presentation: Oozing from IV sites, venipuncture marks, urinary catheter, or surgical wound. |
Uterotonic Pharmacology Matrix
When uterine atony is diagnosed, fundal massage is initiated immediately alongside emergency uterotonic pharmacotherapy. Nurses must master drug dosages, routes, and strict clinical contraindications.
1. Oxytocin (Pitocin)
- Action: First-line agent. Stimulates upper myometrial segment to contract rhythmically.
- Dose & Route: 10 to 40 units in 1,000 mL IV infusion (Lactated Ringer's or Normal Saline) infused at 125 to 250 mL/hour; OR 10 units IM.
- Precautions / Side Effects: NEVER administer undiluted IV push (causes acute severe hypotension, cardiac arrhythmias, and sudden cardiac collapse). Prolonged high-dose IV infusion exerts an antidiuretic hormone (ADH)-like effect, predisposing to water intoxication and severe hyponatremia.
2. Methylergonovine (Methergine)
- Action: Ergot alkaloid producing sustained, tetanic uterine contractions.
- Dose & Route: 0.2 mg IM every 2 to 4 hours (maximum 5 doses / 1.0 mg total).
- STRICT CONTRAINDICATION: Hypertension, Preeclampsia, Gestational Hypertension, or Cardiac Disease. Methergine induces potent peripheral arterial vasoconstriction, triggering severe hypertensive crisis, stroke, or myocardial infarction.
3. 15-Methyl Prostaglandin F2\alpha (Carboprost / Hemabate)
- Action: Prostaglandin derivative stimulating myometrial contractions and vascular smooth muscle constriction.
- Dose & Route: 250 mcg IM or intramyometrially every 15 to 90 minutes (maximum 8 doses / 2.0 mg total).
- STRICT CONTRAINDICATION: Asthma or Reactive Airway Disease. Hemabate induces severe bronchospasm and pulmonary hypertension.
- Side Effects: Profuse watery diarrhea, nausea, vomiting, shivering, flushing, and transient fever (pyrexia).
4. Misoprostol (Cytotec)
- Action: Synthetic prostaglandin E1 analogue causing strong uterine contractions.
- Dose & Route: 800 to 1,000 mcg rectally (or 600 mcg sublingually/orally).
- Advantages & Side Effects: Rapid transmucosal absorption; requires no refrigeration. Side effects include transient high fever (pyrexia), shivering, chills, and hyperthermia.
5. Tranexamic Acid (TXA)
- Action: Antifibrinolytic agent that competitively inhibits plasminogen activation, stabilizing fibrin clots.
- Dose & Route: 1 gram IV diluted in 100 mL Normal Saline or D5W infused over 10 minutes.
- Timing and indication: For clinically diagnosed PPH, give 1 g IV as soon as possible and within 3 hours of birth, in addition to uterotonics, source control, resuscitation, and other standard care. A second 1-g IV dose may be given if bleeding continues after 30 minutes or restarts within 24 hours. Avoid when a clear contraindication to antifibrinolytic therapy exists; TXA is not a uterotonic and is not triggered by blood-loss number alone without clinical assessment.
Staged Obstetric Hemorrhage Response
Use the facility hemorrhage cart, medication kit, laboratory pathway, escalation stages, and massive-transfusion protocol. Fixed blood-loss thresholds help trigger action, but vital signs may remain deceptively normal and a smaller loss can be critical in anemia or ongoing rapid bleeding.
- Recognize and mobilize: Call for help, quantify cumulative loss, assess tone and the 4 Ts, cycle vital signs, maintain warmth, and establish adequate IV access.
- Treat the cause while resuscitating: Massage an atonic uterus; empty the bladder; give oxytocin and additional safe uterotonics; inspect for trauma; evaluate retained tissue and coagulopathy. Give early TXA for clinically diagnosed PPH within the evidence-based window.
- Escalate persistent bleeding: Activate anesthesia, blood bank, operating-room, interventional-radiology, and higher-level support early. Reassess hemoglobin, platelets, fibrinogen, coagulation, ionized calcium, temperature, acid-base state, and perfusion according to the protocol.
- Source control and blood products: Balloon tamponade, repair, evacuation, compression sutures, embolization, vascular control, or hysterectomy may be required. Massive transfusion uses the institution's balanced product strategy and laboratory/viscoelastic guidance; do not memorize one universal ratio as the only safe response.
Document cumulative QBL, treatments, contraindication checks, response, product identifiers, team activation, and debriefing. Continue surveillance for recurrent bleeding, anemia, organ injury, transfusion reaction, and psychological effects.
A nurse is caring for a postpartum patient experiencing significant uterine atony and bleeding following the delivery of a 4,500-gram infant. The patient's blood pressure is 158/98 mmHg, pulse is 112 bpm, and history is positive for preeclampsia. Which uterotonic medication is strictly contraindicated for this patient?
A patient on Postpartum Day 1 experiences acute uterine atony unresponsive to initial oxytocin administration. The nurse notes a history of moderate persistent asthma treated with an albuterol inhaler. Which uterotonic agent should the nurse avoid administering?
A nurse performing a postpartum assessment notes a steady stream of bright red vaginal bleeding in a patient who delivered 1 hour ago. Upon abdominal palpation, the uterine fundus is firm, contracted, and located 1 cm below the umbilicus at midline. Which etiology of postpartum hemorrhage should the nurse suspect?